Please ensure Javascript is enabled for purposes of website accessibility

Does $24.6 Billion in Debt Make Bausch Health Companies Too Risky a Buy?

By Zhiyuan Sun – Apr 30, 2020 at 7:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

How one company's enormous debt stack is preventing a fresh start.

Pharmaceutical provider Bausch Health Companies (BHC -0.86%) is having significant troubles using cash for new growth, because it must devote nearly all of its capital to debt repayments. In addition, its recent clinical program to investigate its anti-inflammatory drug, Virazole, for the treatment of COVID-19 might possess significant flaws. Is the company a safe investment for long-term shareholders? Or will loss of exclusivity on key products and lack of growth potential hamper share appreciation in the long run?

A hospital sign on the outside of a hospital building.

Image source: Getty Images.

What seems to be the problem?

Normally, pharmaceutical companies must commit a large portion of their revenues to research and development. This is because patents covering new drug discoveries last 20 years after the initial date of filing. After that date, branded drugs will see nearly all of their revenues eroded as authorized generic products begin flooding the market to bring down prices and make prescription drugs more affordable.

Hence, branded-drug companies need to allocate massive amounts of capital to conducting clinical trials and bringing new drugs to market in order to protect their competitive moats. With regard to this metric, Bausch Health is performing poorly.

Last year, the company's spending on research and development amounted to just $471 million, or 5.5%, out of its $8.49 billion in revenues. Meanwhile, competitors in the sector spend an average of 20% to 24% on R&D.

Usually, in cases such as this, a pharmaceutical company would raise new debt or equity or find collaborative partners to fund new clinical opportunities. For Bausch Health, however, this is simply not the case. Currently, the company has more than $21 billion in net debt (mostly racked up from levered acquisitions) and is generating merely $3.4 billion in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). Nearly half of this cash flow ($1.6 billion) is used for the payment of interest on existing debt alone.

A company simply cannot have a fresh start while drowning in debt. This is reflected in the performance of the company's ophthalmology, gastrointestinal, dermatologics, and diversified segments. While its gastrointestinal drugs saw growth of more than 20% in 2019, overall revenues grew by a mere 2.6% year over year, well below other pharma companies.

What about Virazole?

One growth catalyst that has investors talking is Virazole, an antiviral used to treat several respiratory illnesses and viral hemorrhagic fever. Because of its demonstrated ability to combat related infections, the drug is being considered  as a way to stop the viral reproduction of the COVID-19 coronavirus. An open-label study currently ongoing in Canada is investigating the drug administered with other standards of care to COVID-19 patients with respiratory distress.

Virazole's potential, however, might be doomed from the start. In a pharmacotherapy recommendation guide published by Nebraska Medicine, Virazole was listed as having mixed results in efficacy against COVID-19. Moreover, serious adverse events, such as anemia, have been associated with the drug. Therefore, it is unlikely Virazole will help Bausch Health's bottom line this year, especially considering there has been no updated guidance as to when its clinical trial will end.

Is there any long-term potential for Bausch Health?

In fact, the company might not meet its revenue and earnings-per-share guidance due to widespread disruptions in the pharmaceutical supply chain related to COVID-19 and the lack of a promising candidate to treat the virus. Although the stock is trading at a mere 4 times forward earnings (non-GAAP), it's unlikely the company's valuation can improve given its subpar levels of growth and too much debt burden. Hence, investors interested in pharmaceutical stocks should instead look for companies with no debt, optimal levels of growth, and reasonable prices.

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
BHC
$6.89 (-0.86%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.